Related Experiment Videos
Metal chelator decreases Alzheimer beta-amyloid plaques
1Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, NY 10021, USA.
Neuron
|June 30, 2001
Abstract:
Transgenic mice developing beta-amyloid (Abeta) plaques are advancing experimental treatment strategies for Alzheimer's disease. The metal chelator, clioquinol, is reported by Cherny et al. (2001) to reduce Abeta plaques, presumably by chelation of Abeta-associated zinc and copper. This and other recent Abeta-modulating treatment approaches are discussed.